Clik here to view.
Black Diamond cuts workforce, prioritizes lung cancer drug
Black Diamond Therapeutics is cutting an unspecified number of workers, including several executives, and making changes to its pipeline in an effort to extend its cash runway. Fang Ni As part of the...
View ArticlePfizer's former top executives pitched changes to board as part of activist's...
Pfizer’s former CEO and CFO relayed proposals from activist investor Starboard Value to several members of the company’s board on Sunday, according to a source familiar with the conversations, as part...
View ArticleExclusive: A small San Diego biotech wants to change how Parkinson’s disease...
A protein called alpha-synuclein that accumulates and ravages the brains of some people with Parkinson’s disease is the target of several experimental drugs. Until recently, the only way to detect it...
View ArticleJohn Maraganore's RNAi biotech City Therapeutics debuts with $135M Series A
City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of next-generation RNAi therapies that could act on tissues apart from the liver,...
View ArticleCompounding pharmacy group sues FDA for ending Eli Lilly's GLP-1 drug shortage
A trade group for large compounding pharmacies sued the FDA over its move to take Eli Lilly’s blockbuster GLP-1 drug off its shortage list, hamstringing compounders’ ability to create their own,...
View ArticleJim Wilson secures $100M for global approach aimed at reviving gene therapy...
A gene therapy pioneer thinks he has a solution to the field’s struggle to commercialize breakthrough cures: Go global. Jim Wilson’s Philadelphia-based company GemmaBio on Tuesday announced up to $100...
View ArticleFDA again raises doubts on Stealth's ultra-rare disease drug ahead of adcomm
Data submitted to the FDA by Stealth BioTherapeutics for its ultra-rare disease drug likely aren’t sufficient for an approval or even an accelerated approval, agency staff said in briefing documents...
View ArticlePfizer culls RSV treatment from ReViral acquisition
Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 million acquisition of ReViral in 2022. The New York drug company — which is...
View ArticleClik here to view.
GSK's RSV vaccine Arexvy shows long-term protection in Phase 3 trial
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST 2024 Annual Meeting. In the Phase 3 trial, called AReSVi-006, a dose of...
View ArticleBaxter plots recovery after Hurricane Helene, MilliporeSigma’s €290M facility
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Baxter said that it is increasing manufacturing at its sites outside...
View ArticleSen. Warren urges FTC to ‘carefully scrutinize’ Novo-Catalent deal over...
Sen. Elizabeth Warren (D-MA) has put the spotlight on Novo Holdings’ acquisition of Catalent, expressing concerns that the deal could give Novo Nordisk “unprecedented visibility” into its competitors’...
View ArticleImmatics heads to Phase 3 with melanoma cell therapy, seeks to raise $150M
Immatics said its PRAME-targeted T cell therapy shrank tumors by at least 30% in just over half of melanoma patients in an early-stage trial, and the company plans to start a pivotal study by the end...
View ArticleEli Lilly inks another obesity pact, doubling down on small Swiss partner
Eli Lilly is returning to KeyBioscience, a nimble Swiss biotech, seven years after originally linking arms with the startup to work on dual amylin calcitonin receptor agonists for obesity and other...
View ArticleSeven patients diagnosed with blood cancer after Skysona treatment, new data...
Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood cancer months or years after treatment, according to data published on Wednesday...
View ArticleClik here to view.
Updated: FDA approves Roche's new treatment for subset of breast cancer patients
The FDA has approved Roche’s inavolisib plus Pfizer’s Ibrance and fulvestrant in a subtype of breast cancer over a month before the target action date, the agency announced Thursday. The treatment,...
View ArticleFDA adcomm supports first potential drug for ultra-rare, fatal Barth syndrome
Heartbreaking anecdotes from the patients, parents and doctors of children with the ultra-rare and fatal Barth syndrome won over an FDA advisory committee on Thursday, likely setting up a tough...
View ArticleSanofi discontinues Denali-partnered MS trial after Phase 2 failure
Sanofi is ending a Phase 2 clinical trial that’s testing a drug from Denali for multiple sclerosis, putting a stop to the development plan. Denali said in an SEC filing Thursday that Sanofi notified...
View ArticleBiotech startups Upstream, CAMP4 price Friday IPOs
Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in what appears to be a recovery for startups trying to raise capital on the...
View ArticleClik here to view.
Lilly follows the trend of new AI hires; Pfizer fills key UK position as...
Thomas Fuchs → Eli Lilly has joined the club of pharma companies that have lined up AI execs. Thomas Fuchs will be Lilly’s first-ever chief AI officer on Oct. 21 and comes from the Icahn School of...
View ArticleExclusive: PhRMA attacks federal government's response to rebate model for 340B
The pharma industry’s DC-based lobbying group urged the federal government on Friday to get on board with alternative models for 340B drug price discounts. In a letter to the Health Resources and...
View Article